May 2022 FAQs
Introduction
- What is the strength of evidence available on the risk of GI bleeding with direct oral anticoagulants?
- Do data support the use of oral vancomycin prophylaxis for primary prevention of Clostridium difficile infection CDI in high-risk patients?
- What new evidence is available to support the use of direct oral anticoagulants (DOACs) in pediatric patients for venous thromboembolism (VTE) treatment and prevention?